Spots Global Cancer Trial Database for transcatheter arterial chemoembolization
Every month we try and update this database with for transcatheter arterial chemoembolization cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | NCT02537158 | Hepatocellular ... | Sorafenib TACE | 18 Years - 75 Years | ChineseAMS | |
| Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | NCT01858207 | Hepatocellular ... | Transcatheter A... Radiofrequency ... Doxorubicin | 18 Years - | Chang Gung Memorial Hospital | |
| Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | NCT02997956 | Hepatocellular ... | Tocilizumab Transcatheter A... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | NCT00646100 | Hepatocellular ... | transcatheter a... | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | NCT05171335 | Hepatocellular ... | Lenvatinib Transcatheter A... | 18 Years - | The Methodist Hospital Research Institute | |
| Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM | NCT06021015 | Colorectal Canc... | Irinotecan and ... Irinotecan and ... | 18 Years - 80 Years | Zhongda Hospital | |
| The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | NCT06041425 | Hepatocellular ... Transcatheter A... Pain Inflammation | Oxycodone Sufentanil | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma | NCT00829465 | Unresectable He... | Licartin Transcatheter a... | 18 Years - 85 Years | Eastern Hepatobiliary Surgery Hospital | |
| TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | NCT05984511 | Hepatocellular ... Hepatic Portal ... Tumor Thrombus | I-125 Seeds Bra... Transcatheter a... Atezolizumab pl... | 18 Years - 75 Years | Third Affiliated Hospital, Sun Yat-Sen University | |
| Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion | NCT00501813 | Hepatocellular ... | Hepatectomy TACE combined w... | 18 Years - 70 Years | Sun Yat-sen University | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy | NCT03235167 | Hepatocellular ... | CpG DNA transcatheter a... Placebo - Conce... | 55 Years - 75 Years | Dalian University | |
| Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma | NCT02109146 | Hepatocellular ... Transcatheter A... | Prophylactic Tr... Observation | 18 Years - 80 Years | Zhejiang University | |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC | NCT04597970 | Transarterial C... Hepatocellular ... | cTACE-HAIC | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion | NCT00501813 | Hepatocellular ... | Hepatectomy TACE combined w... | 18 Years - 70 Years | Sun Yat-sen University | |
| Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | NCT05171335 | Hepatocellular ... | Lenvatinib Transcatheter A... | 18 Years - | The Methodist Hospital Research Institute | |
| TACE Combined With Iodine-125 Seeds Implantation for HCC | NCT03322280 | Hepatocellular ... Portal Vein Occ... Tumor Thrombus | TACE combined w... TACE | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma | NCT00556803 | Hepatocellular ... Liver Cancer | radiofrequency ... TACE after RFA | 18 Years - 75 Years | Sun Yat-sen University | |
| Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication | NCT00769730 | Hepatocellular ... Hepatitis B Vir... | - | Kaohsiung Medical University Chung-Ho Memorial Hospital | ||
| Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas | NCT05352204 | Carcinoma, Hepa... | transcatheter a... | - | Zhejiang University | |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC | NCT04597970 | Transarterial C... Hepatocellular ... | cTACE-HAIC | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | NCT02537158 | Hepatocellular ... | Sorafenib TACE | 18 Years - 75 Years | ChineseAMS | |
| Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | NCT05171335 | Hepatocellular ... | Lenvatinib Transcatheter A... | 18 Years - | The Methodist Hospital Research Institute | |
| TACE Combined With Iodine-125 Seeds Implantation for HCC | NCT03322280 | Hepatocellular ... Portal Vein Occ... Tumor Thrombus | TACE combined w... TACE | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas | NCT05352204 | Carcinoma, Hepa... | transcatheter a... | - | Zhejiang University | |
| TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma | NCT00556803 | Hepatocellular ... Liver Cancer | radiofrequency ... TACE after RFA | 18 Years - 75 Years | Sun Yat-sen University | |
| Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | NCT02638857 | Recurrence Hepa... Advanced Hepato... | TACE Dendritic Cell lipiodol Mitomycin (MMC) Epirubicin(EADM... Precision Multi... | 18 Years - 65 Years | Second Military Medical University | |
| A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC | NCT03116984 | Hepatocellular ... | Transcatheter a... External- beam ... | 18 Years - | Shanghai Zhongshan Hospital | |
| Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy | NCT03235167 | Hepatocellular ... | CpG DNA transcatheter a... Placebo - Conce... | 55 Years - 75 Years | Dalian University | |
| Best Therapy for Patients With Neuroendocrine Tumors | NCT00815620 | Neuroendocrine ... | 18 Years - 90 Years | Zentralklinik Bad Berka | ||
| TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens | NCT06071052 | Liver Metastasi... | TACE and HAIC C... | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy | NCT05811481 | Hepatocellular ... Transcatheter A... Regorafenib | TACE Regorafenib | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication | NCT00769730 | Hepatocellular ... Hepatitis B Vir... | - | Kaohsiung Medical University Chung-Ho Memorial Hospital | ||
| TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | NCT04417764 | Advanced Hepato... | Transcatheter a... PD-1 knockout e... | 18 Years - 70 Years | Central South University | |
| Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas | NCT05352204 | Carcinoma, Hepa... | transcatheter a... | - | Zhejiang University | |
| Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC | NCT05420922 | Hepatocellular ... Programmed Cell... Effects of Immu... | Lenvatinib Oral... PD-1 inhibitor Local treatment | 18 Years - | Tongji Hospital | |
| Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) | NCT06090656 | Hepatocellular ... | Bevacizumab com... Transcatheter a... | 18 Years - | Sun Yat-sen University | |
| Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma | NCT05670561 | Hepatocellular ... Transcatheter A... Pain | Esketamine Sufentanil | 18 Years - 80 Years | The Second Affiliated Hospital of Chongqing Medical University | |
| Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | NCT02584556 | Hepatocellular ... | systemic chemot... Transcatheter A... | 18 Years - 75 Years | Guangxi Medical University | |
| The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | NCT06041425 | Hepatocellular ... Transcatheter A... Pain Inflammation | Oxycodone Sufentanil | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy | NCT03235167 | Hepatocellular ... | CpG DNA transcatheter a... Placebo - Conce... | 55 Years - 75 Years | Dalian University | |
| TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | NCT04417764 | Advanced Hepato... | Transcatheter a... PD-1 knockout e... | 18 Years - 70 Years | Central South University | |
| TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma | NCT01833286 | Hepatocellular ... Surgery Ablation | TACE+RFA re-resection | 18 Years - 75 Years | Sun Yat-sen University | |
| Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC | NCT05420922 | Hepatocellular ... Programmed Cell... Effects of Immu... | Lenvatinib Oral... PD-1 inhibitor Local treatment | 18 Years - | Tongji Hospital | |
| Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | NCT02638857 | Recurrence Hepa... Advanced Hepato... | TACE Dendritic Cell lipiodol Mitomycin (MMC) Epirubicin(EADM... Precision Multi... | 18 Years - 65 Years | Second Military Medical University | |
| TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma | NCT01833286 | Hepatocellular ... Surgery Ablation | TACE+RFA re-resection | 18 Years - 75 Years | Sun Yat-sen University | |
| Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis | NCT00518557 | Hepatocellular ... | Transcatheter A... | 18 Years - 70 Years | Southeast University, China | |
| Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | NCT02862613 | Precision Cells Transcatheter A... Advanced Liver ... | TACE Precision Cells | 18 Years - 65 Years | Shanghai International Medical Center | |
| Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC | NCT05420922 | Hepatocellular ... Programmed Cell... Effects of Immu... | Lenvatinib Oral... PD-1 inhibitor Local treatment | 18 Years - | Tongji Hospital | |
| Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | NCT02873442 | Precision Cell ... Transcatheter A... Advanced Liver ... | TACE Precision Cells | 18 Years - 65 Years | Ningbo Cancer Hospital | |
| A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma | NCT04799548 | Advanced Gastri... | Transcatheter A... Tislelizumab | 18 Years - 75 Years | Shanghai Zhongshan Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
